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Abstract 
 
Juvenile Myelomonocytic Leukemia (JMML) is a lethal myeloproliferative disorder (MPD) of 
children, characterized by hyperproliferation of myelomonocytic cells and hypersensitivity to 
Granulocyte-Monocyte Colony-Stimulating Factor (GM-CSF).  JMML is frequently associated 
with gain-of-function mutations in PTPN11, which encodes the protein tyrosine phosphatase, 
Shp2, and which is known to positively regulate Ras signaling.  The role of MAPK signaling in 
gain-of-function mutant Shp2-induced leukemogenesis is well established.  In addition, phospho-
Akt levels are elevated in the presence of gain-of-function Shp2 mutations, suggesting a role for 
Phosphatidyl-Inositol-3-Kinase (PI3K) signaling (Yang, et al, 2008).  Class IA PI3K is a lipid 
kinase heterodimer composed of one of two regulatory subunits—p85 alpha or p85 beta—and 
one of three catalytic subunits—p110 alpha, p110 beta, or p110 delta.  PI3K mediates 
proliferative and anti-apoptotic signals.  We have found that there is increased interaction 
between the p85 alpha regulatory subunit and the p110 alpha catalytic subunit in gain-of-
function mutant Shp2-expressing cells compared to WT Shp2-expressing cells.  The p85 alpha 
regulatory subunit, along with its splice variants, p55 alpha and p50 alpha, is encoded by the 
gene Pik3r1.  To investigate the hypothesis that p85 alpha-dependent PI3K signaling contributes 
to gain-of-function mutant Shp2-induced GM-CSF hypersensitivity, WT and Pik3r1-/- fetal 
liver-derived hematopoietic progenitor cells were transduced with WT Shp2 or gain-of-function 
mutant Shp2 E76K.  Ablation of all the Pik3r1 isoforms resulted in a significant, but incomplete, 
correction of GM-CSF hypersensitivity in Shp2 E76K-expressing cells.  Consistently, upon 
genetic disruption of Pik3r1, Akt phosphorylation was reduced in both WT Shp2- and Shp2 
E76K-expressing cells compared to that seen in Pik3r1+/+ cells, but was not completely absent.  
Additionally, Erk activation was reduced in Pik3r1-/- cells expressing Shp2 E76K compared to 
that in Pik3r1+/+ cells, indicating that interruption of Shp2-mediated PI3K signaling affects the 
MAPK pathway as well, which likely contributes to the reduction in GM-CSF-stimulated 
proliferation in the Pik3r1-/- cells.  Finally, treatment with the PI3K inhibitor, LY294002 
resulted in complete abrogation of Akt phosphorylation in Pik3r1-/- cells transduced with Shp2 
E76K, indicating that residual PI3K activity in the absence of Pik3r1 likely contributes to the 
incomplete correction of GM-CSF hypersensitivity and suggesting that although p85 alpha plays 
an important role in gain-of-function mutant Shp2-induced hyperactivation of PI3K signaling, 
additional p85 alpha-independent mechanisms contribute as well. 
 
 
